Safety, acceptability, and adherence to a dolutegravir-based regimen among adults living with HIV at Kenyatta National Hospital
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20223527Keywords:
Acceptance, Adherence, Adverse drug reactions, Dolutegravir, HIVAbstract
Background: Dolutegravir-based therapy was rolled-out in Kenya in 2017 with limited safety studies in the country and Africa. This study sought to assess and profile the adverse drug reactions, acceptability, and adherence to the newly rolled out dolutegravir-based regimens among HIV patients attending Kenyatta National Hospital.
Methods: This was a cross-sectional study conducted between November and December 2019 at Kenyatta national hospital comprehensive care clinic. Through systematic random sampling, a sample of 219 adult HIV patients on a dolutegravir-based antiretroviral regimen were recruited and interviewed for the experience of adverse drug reactions, adherence, and acceptance of the dolutegravir-based regimen using a researcher-administered questionnaire. Descriptive analysis was conducted using IBM SPSS V 21 software. The alpha was set at p≤0.005.
Results: A-quarter of the patients (24.7%, n=54) reported experiencing drug-related adverse drug reactions. The most frequent adverse reaction was insomnia (24.1%, n=19), followed by headaches (19.0%, n=15) and skin reactions (13.9%, n=11). The least cited was vomiting (2.5%. n=2). Most (87.3%, n=69) of the adverse reactions were mild (grade 1 reactions), with very few (7.6%, n=6) of them being severe (toxicity grade 3). Only 2 (0.9%) of the reactions resulted in the dolutegravir-based regimen switch. Adherence was high (97.3%, n=213), and 90.4% (n=198) of patients reported to accept the new dolutegravir-based regimen.
Conclusions: Adult patients living with HIV on a dolutegravir-based regimen experienced some adverse drug reactions; mostly mild and resolved without medical intervention. Generally, the regimen had an acceptable safety profile, and a high adherence rate was reported.
Metrics
References
Mongi A, Nyamu D, Karimi P, Maru S. Evaluation of the management of hypertension among diabetic and non-diabetic adult outpatients at a referral hospital in Kenya. African J Pharmacol Ther. 2016;5(2).
Kandel CE, Walmsley SL. Drug design, development and therapy dovepress dolutegravir-a review of the pharmacology, efficacy, and safety in the treatment of HIV. Drug Des Dev Ther. 2015;9:3547.
Kenya Population-Based HIV Impact Assessment. KENIA 2018 PREL REP fin_alt2_USAID.indd 1. 2018. Available from: http://www.nascop.or.ke/KENPHIA. Accessed on 21 September 2022.
García JT, Bascuñana J. Safety and tolerability: current challenges to antiretroviral therapy for the long-term management of HIV infection. AIDS Rev. 2016;18(3):127-37.
Paul NI, Ugwu RO. Dolutegravir (DTG) based fixed dose combination (FDC) of tenofovir/lamivudine/ dolutegravir (TLD) and viral load suppression in children in Port Harcourt, Nigeria. J Sci Res Rep. 2020;52-9.
Raesima MM, Ogbuabo CM, Thomas V, Forhan SE, Gokatweng G, Dintwa E, et al. Dolutegravir use at conception- additional surveillance data from Botswana. N Engl J Med. 2019;381(9):885-7.
Chawla A, Wang C, Patton C, Murray M, Punekar Y, de Ruiter A, et al. A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population. Infect Dis Ther. 2018;7(2):183-95.
Israel GD. Determining Sample Size 1. Available from: https://www.gjimt.ac.in/wp-content/uploads/ 2017/10/2_Glenn-D.-Israel_Determining-Sample-Size.pdf. Accessed on 21 September 2022.
WHO. Side effects- pocket guide (2017) | HIV i-Base. 2017. Available from: https://i-base.info/pocket-side-effects/. Accessed on 21 September 2022.
Chalker JC, Andualem T, Gitau LN, Ntaganira J, Obua C, Tadeg H, et al. Measuring adherence to antiretroviral treatment in resource-poor settings: The feasibility of collecting routine data for key indicators. BMC Health Serv Res. 2010;10(1):1-11.
Julia C, Batista B, Correa RG, Ramalho Evangelista L, Fleck K, Silva L, et al. The Brazilian experience of implementing the active pharmacovigilance of dolutegravir. Medicine. 2019;98(10).
Kumarasamy N, Prabhu S, Chandrasekaran E, Poongulali S, Pradeep A, Chitra D, et al. Safety, tolerability, and efficacy of generic dolutegravir-containing antiretroviral therapy regimens among south Indian human immunodeficiency virus-infected patients. Clin Infect Dis. 2019;68(6):1048-51.
Abubakar AR, Simbak NB, Haque M. Adverse drug reactions: predisposing factors, modern classifications and causality assessment. Res J Pharm Technol. 2014;7(9):14.
De Boer MGJ, Van Den Berk GEL, Van Holten N, Oryszcyn JE, Dorama W, Ait Moha D, et al. Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. AIDS. 2016;30(18):2831-4.
Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink HJ, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18(1):56-63.
Cailhol J, Rouyer C, Alloui C, Jeantils V. Dolutegravir and neuropsychiatric adverse events: a continuing debate. AIDS. 2017;31(14):2023-4.
Nyongesa MK, Mwangi P, Wanjala SW, Mutua AM, Newton CRJC, Abubakar A. Prevalence and correlates of depressive symptoms among adults living with HIV in rural Kilifi, Kenya. BMC Psychiatr. 2019;19(1):1-10.
Wasti SP, Simkhada P, Randall J, Freeman JV, Van Teijlingen E. Barriers to and facilitators of antiretroviral therapy adherence in Nepal: a qualitative study. J Health Popul Nutr. 2012:410-9.
